Insights On Enterprise Solutions
-
Global Manufacturing Excellence Across Quality, Efficiency, And Cost Of Goods Sold
3/26/2026
Learn strategies to strengthen global biologics manufacturing through consistent quality, advanced technologies, and efficient tech transfer to improve operations and commercial readiness.
-
Ensure Successful Viral Clearance
3/26/2026
A decade of viral clearance data comparing established and emerging operations, highlighting LRV performance, key process risks, and practical insights to strengthen downstream safety.
-
Deciphering The Complexity Of Therapeutic Biologics
3/26/2026
This session breaks down essential analytical approaches that strengthen biologics development, from defining critical quality attributes to supporting comparability and regulatory readiness.
-
Engineering The Next Wave Of CHO Performance
3/24/2026
By combining improved productivity with speed and reliability, S-CHOice® 2G helps biopharmaceutical companies optimize their manufacturing strategies, reduce overall costs, and respond more effectively to market demands.
-
Catalent Capabilities Update March 2026: Analytical Services
3/24/2026
A biologics analytics leader showcases development, testing, and characterization capabilities, emphasizing quality, regulatory compliance, and integrated support from discovery to commercialization.
-
Lonza Capabilities Update March 2026: Cell & Gene Therapy
3/24/2026
A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.
-
Process Optimization For Monoclonal Antibody (mAb) Commercial Manufacturing
3/20/2026
Get access to the tools and expertise needed to support process development for biologic therapies from the clinical trial phase to commercialization.
-
Reducing Risk, Enhancing Flexibility: A New Approach To Custom Media Manufacturing
3/20/2026
The session highlights how tailored media solutions, combined with strong scientific understanding and scalable manufacturing practices, can support more efficient, reliable, and future-ready bioprocess development.
-
Accelerating Vector Construction-To-IND: Achieving A 9-Month Timeline Through Integrated Cell Line Development
3/19/2026
Uncover how tighter alignment between vector construction and cell banking improved development efficiency, strengthened risk management, and enhanced early-stage program outcomes.
-
Enhanced Biotherapeutic Protein Expression Using Advanced Vector Systems
3/18/2026
Learn how optimized expression vector design and data-driven strategies can significantly enhance product titre, quality, and long-term gene expression stability in GS-CHO cell-based manufacturing.